# Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients

> **NCT07233499** · PHASE2 · RECRUITING · sponsor: **Ain Shams University** · enrollment: 56 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Nebivolol 5 mg

## Key facts

- **NCT ID:** NCT07233499
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07233499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07233499, "Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07233499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*